Setup

Rayonier Advanced Materials (RYAM) is in formal strategic review with Morgan Stanley + Wachtell Lipton. American Industrial Partners made an unsolicited $11-12 cash bid in November 2025; the board rejected, AIP filed a Schedule 13D at 5.07% in February, and the board capitulated to a formal process in April after CEO Scott Sutton resigned 3.5 months into the role. A trade-policy catalyst lands May 18.

What the Q1 call says

CFO Marcus Moeltner, running the interim Office of the CEO, opened the May 6 prepared remarks with "formal review of strategic alternatives to maximize shareholder value" and named Morgan Stanley as financial advisor. Third-party interest was confirmed. Process timing was declined when pressed — standard auction protocol.

Q1 2026 generated $12M adjusted free cash flow against -$88M for full-year 2025. Liquidity improved to $160M. Cellulose Specialties average sales price was +17% year-over-year (see note below); the majority of 2026 CS volume is locked at meaningfully higher pricing; Q2 CS volume is guided +15-20% sequentially. Pending fluff pricing announcements: +$55/MT China, +$120/MT North America and Europe — confirmed by Suzano ($50 + new $50 in Western markets) and Mercer (+8% sequential NBSK in Europe).

New framing: "RYAM is the sole remaining U.S. producer of high-purity dissolving wood pulp," tied to "critical infrastructure and certain defense-related applications."

What the market thinks

Coverage: one analyst (RBC McKellar, $14 target, raised from $11 in March). August 21 options show call-heavy positioning: P/C 0.36 OI, $11 call 336 contracts (the rejected AIP bid level), $17 call 127 contracts (a premium-deal scenario). ATM IV 104%. Delta-implied probabilities: ≈36% stock above $11 by Aug 21, ≈27% above $14, ≈18% above $17.

Market-implied P(deal) depends on the assumed deal price. A binomial anchored at the standing AIP bid ($12.50 deal / $5.50 no-deal) solves P(deal) ≈ 54%. Pushed to $14 it falls to ≈45%. The plausible range is 45-55%. Our scenario stack sums to 55% (premium 25% + base 30%) — so the edge is not in central deal probability. It sits in the tails: we assign ≈25% to the premium scenario above $14 versus delta-adjusted market ≈20%, and ≈4% to the catastrophic tail below $5 versus implied ≈10%.

An independent asset anchor: CS standalone at peer multiple (Borregaard 10-11x EV/EBITDA, ≈$200M RYAM CS run-rate EBITDA) implies ≈$2.0B TEV. Net of $779M debt, that's ≈$19/sh standalone equity ignoring the loss-making other segments. Realized deal value will price below this — acquirers have to absorb commodity-segment liabilities — but the headroom above AIP's $11-12 rejected bid is real.

Why the gap exists

Coverage thinness. One analyst on the name; synthesis across M&A + trade case + operational inflection has not converged in published research.

The AD/CVD preliminary determination is scheduled for May 18, three days from this writing. The relevant precedent is not the ITC injury vote (cleared Sep 26, 2025) but the Brazil CVD prelim, which Commerce returned affirmative on March 25, 2026 — same case family, same investigators, eight weeks ago. Petitioner-alleged AD margins: 168% Brazil, 226% Norway (Borregaard). The binary question (affirmative/negative) is less central than the margin level — Commerce typically returns 20-80% of alleged. Moeltner described AD/CVD trajectory as "positive" but did not name the date; Borregaard's CEO publicly confirmed waiting for it. The May 18 catalyst is buried in management's optimistic-but-vague framing and absent from sell-side notes.

Risks (ranked by impact)

1. $700M term loan CIC language unverified. The 2024 credit agreement may contain change-of-control mandatory prepayment plus make-whole. If yes, it deters strategic acquirers and compresses the premium-deal scenario — which carries roughly 16% of expected value in our scenario. This is load-bearing for the tail edge. Not yet read.
2. Process fails. ≈20% scenario probability. Stock reverts toward $5-7. Debt overhang limits standalone equity recovery.
3. AD prelim margin below 25% or postponement. Trade-protection narrative weakens for bidders. Margin level matters more than binary affirmative.
4. CS pricing is mix, not pricing power. Borregaard reported -4% YoY same quarter; RYAM's +17% reflects Temiscaming exit and fluff pivot, not sector tailwind. Not durable peer-multiple justification.

Catalysts

• 2026-05-18: Commerce AD preliminary determination on Brazil/Norway DWP imports
• 2026-06 through 07: Likely first-round bid window in the Morgan Stanley auction
• 2026-08-03: Final AD/CVD determination
• 2026-08-04: Q2 2026 earnings call (deal-process update)
• Through 2027-04-30: Definitive agreement outside-date window

What would change our mind

Term loan exhibit 10.x reveals CIC mandatory prepayment + make-whole — caps the premium tail and compresses the load-bearing scenario. AD prelim is delayed or returns margin below 25% — breaks the trade-protection narrative. Schedule 13D/A from AIP showing position reduction — process disengagement. 8-K signaling process stall (advisor changes, extended outside dates, capital structure action announced before a sale agreement). Insider Form 4 selling from the interim Office of the CEO.

Evidence